Monitoring Children with Pulmonary TB After Starting ATT
Children with pulmonary TB on standard drug-susceptible treatment require clinical monitoring at regular intervals (monthly visits) with symptom assessment and weight tracking, while biochemical monitoring (liver and renal function tests) should be performed only in children with pre-existing liver/kidney disease or when clinically indicated by symptoms—routine biochemical monitoring is NOT required in otherwise healthy children with normal baseline tests. 1
Clinical Monitoring Framework
Monthly Clinical Assessment
- Weight monitoring at each visit to adjust drug dosing (mg/kg) and assess nutritional recovery
- Symptom review: fever, cough, malaise, vomiting (not directly medication-related), abdominal pain, jaundice
- Adherence assessment: Consider urine testing for drug metabolites if non-adherence suspected 2
- Growth parameters: Failure to gain weight correlates with higher recurrence risk 3
Specific Clinical Surveillance by Drug
For Ethambutol (if used):
- Baseline visual acuity testing with Snellen chart before starting 1
- Educate parents/caregivers to report visual changes immediately
- In young children unable to report symptoms, rely on parental observation for behavioral changes suggesting vision problems
- Stop ethambutol immediately if any visual field or color vision deterioration 4
For all hepatotoxic drugs (Rifampicin, Isoniazid, Pyrazinamide):
- Educate family about hepatotoxicity symptoms: unexplained vomiting, abdominal pain, jaundice
- No routine liver function monitoring needed if baseline tests normal and no pre-existing liver disease 1
Biochemical Monitoring - Risk-Stratified Approach
Children Requiring Regular Biochemical Monitoring
Liver Function Tests (weekly × 2 weeks, then biweekly × 2 months):
- Pre-existing chronic liver disease
- Baseline AST/ALT ≥2× upper limit of normal
- HIV co-infection on hepatotoxic antiretrovirals
Renal Function Tests (periodic monitoring):
- If streptomycin or other aminoglycosides used
- Pre-existing renal impairment 1
When to Check Biochemistry in Previously Healthy Children
Check liver function immediately if:
- Fever, malaise, vomiting (not directly medication-related)
- Abdominal pain
- Jaundice
- Unexplained clinical deterioration 1
Management algorithm for elevated transaminases:
- AST/ALT 2-5× normal: Recheck weekly until normalized
- AST/ALT >5× normal OR elevated bilirubin: Stop all hepatotoxic drugs immediately 1
Treatment Response Monitoring
Bacteriological Monitoring
- Not routinely required in children with pulmonary TB (rarely smear-positive, cavitation uncommon) 1
- If initial smear/culture positive: Repeat at 2 months to document conversion
- Consider gastric aspirates/induced sputum if treatment failure suspected
Radiological Monitoring
- Not routinely recommended during treatment
- Reserve chest X-ray for clinical deterioration or suspected treatment failure
- Post-treatment imaging only if clinically indicated
Critical Pitfalls to Avoid
Over-monitoring with routine biochemistry: This increases costs without improving outcomes in healthy children with normal baseline tests 1
Missing drug-induced hepatitis: The key is clinical vigilance for symptoms, not routine testing. Educate families thoroughly about warning signs 1
Inadequate dose adjustment: Recalculate doses with weight gain—subtherapeutic concentrations common with guideline-recommended mg/kg dosing 5
Ethambutol in young children without proper counseling: Always educate parents about vision monitoring, even when child cannot self-report 1
Assuming adherence: Consider objective adherence monitoring (urine drug testing) if treatment response poor 2
Special Monitoring Considerations
For severe/disseminated TB or TB meningitis:
- More intensive clinical monitoring required
- Consider therapeutic drug monitoring if available, especially with slow response 6
Post-treatment surveillance: